Telix Pharmaceuticals Limited, a radiopharmaceutical company, develops molecularly targeted radiation (MTR) products for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company focuses on developing diagnostic and therapeutic products using MTR. Its lead products include TLX591-CDx for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX66-CDx to treat bone marrow conditioning and rare diseases; TLX250, which is in Phase II clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX250-CDx that is in Phase III clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX591, which is in Phase III clinical trials for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX101 that is in Phase I/II clinical trials and TLX101-CDx for the diagnosis and treatment of glioblastoma (brain cancer); and TLX66, which is in Phase I/IIa clinical trials for the treatment of bone marrow conditioning and rare diseases. The company also develops TLX592, a prostate cancer therapy candidate for targeted alpha therapy; TLX591-Sx, a positron emission tomography (PET) tracer that delivers PET and fluorescent (optical) imaging; and TLX599-CDx, an investigational prostate cancer imaging agent that uses single photon emission computed tomography. It has a strategic license and commercial partnership with China Grand Pharmaceutical and Healthcare Holdings Limited for developing a portfolio of MTR products; scientific and clinical research collaboration with Mauna Kea Technologies; and strategic collaboration agreement with Lightpoint Medical, Ltd. The company was founded in 2015 and is headquartered in North Melbourne, Australia.

CEO

ISIN

AU000000TLX2

WKN

000A2H7JK

Listings

0 Comments

Share your thoughts

FAQ

What is Telix Pharmaceuticals stock price today?▼

The current price of T3X.F is €7.59 EUR — it has decreased by -2.96% in the past 24 hours. Watch Telix Pharmaceuticals stock price performance more closely on the chart.

What is Telix Pharmaceuticals stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on exchange Telix Pharmaceuticals stocks are traded under the ticker T3X.F.

Is Telix Pharmaceuticals stock price growing?▼

T3X.F stock has fallen by -4.14% compared to the previous week, the month change is a +26.61% rise, over the last year Telix Pharmaceuticals has showed a -38.58% decrease.

What is Telix Pharmaceuticals market cap?▼

Today Telix Pharmaceuticals has the market capitalization of 2.57B

When is the next Telix Pharmaceuticals earnings date?▼

Telix Pharmaceuticals is going to release the next earnings report on August 20, 2026.

What were Telix Pharmaceuticals earnings last quarter?▼

T3X.F earnings for the last quarter are -0.01 EUR per share, whereas the estimation was 0.03 EUR resulting in a -135.4% surprise. The estimated earnings for the next quarter are N/A EUR per share.

What is Telix Pharmaceuticals revenue for the last year?▼

Telix Pharmaceuticals revenue for the last year amounts to 909.82M EUR.

What is Telix Pharmaceuticals net income for the last year?▼

T3X.F net income for the last year is -8.08M EUR.

When did Telix Pharmaceuticals complete a stock split?▼

Telix Pharmaceuticals has not had any recent stock splits.